IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

Core Insights - IDEAYA Biosciences has submitted an investigational new drug (IND) application for IDE574, a potential first-in-class KAT6/7 dual inhibitor, to the FDA, with plans to initiate a Phase 1 trial in Q1 2026 [1][7] Group 1: Product Development - IDE574 is designed to selectively inhibit KAT6 and KAT7, which are involved in tumor cell proliferation and survival, while sparing other KAT family members [2][3] - Preclinical studies indicate that dual inhibition of KAT6 and KAT7 by IDE574 disrupts tumor lineage identity and shows significant anti-tumor activity in lung and breast cancer models [2][3] - The company aims to present preclinical data on IDE574's pharmacologic profile and anti-tumor activity at a medical conference in the first half of 2026 [3][7] Group 2: Company Overview - IDEAYA Biosciences focuses on precision medicine in oncology, emphasizing the discovery and development of targeted therapies aligned with genetic disease drivers [4] - The company has developed a pipeline of product candidates targeting synthetic lethality and antibody-drug conjugates for solid tumor indications [4]